胆香鼻炎片联合糠酸莫米松治疗过敏性鼻炎的临床研究

Clinical study on Danxiang Biyan Tablets combined with mometasone furoate in treatment of allergic rhinitis

目的探讨胆香鼻炎片联合糠酸莫米松治疗过敏性鼻炎的安全性与有效性。方法选取2019年12月-2020年12月在平煤神马集团总医院诊治的121例过敏性鼻炎患者,按照入组顺序分成对照组(61例)和治疗组(60例)。对照组患者采用糠酸莫米松鼻喷雾剂喷鼻治疗,2揿/次,1次/d,待症状有效控制后药量改为1揿/次,1次/d;治疗组在对照组患者基础上口服胆香鼻炎片,4片/次,3次/d。两组患者连续治疗6周。观察两组患者临床疗效,比较治疗前后两组患者RQLQ评分和症状评分,血清白细胞介素-6(IL-6)、白细胞介素-27(IL-27)和γ干扰素(IFN-γ)水平及不良反应情况。结果治疗后,对照组临床有效率为81.97%,明显低于治疗组的95.00%(P<0.05);治疗后,两组患者RQLQ评分和症状评分均较治疗前显著降低(P<0.05),且治疗组降低更显著(P<0.05);治疗后,两组患者血清IL-6、IFN-γ水平显著降低,而IL-27显著升高(P<0.05),且治疗组比对照组改善更显著(P<0.05)。治疗期间,对照组不良反应发生率明显高于治疗组(19.67%vs5.00%,P<0.05)。结论胆香鼻炎片联合糠酸莫米松鼻喷雾剂治疗过敏性鼻炎疗效确切,可显著改善患者临床症状和生存质量,且不良反应发生率低。

Objective To explore the safety and efficacy of Danxiang Biyan Tablets combined with mometasone furoate in treatment of allergic rhinitis. Methods Patients(121 cases) with allergic rhinitis in General Hospital of Pingmei Shenma Group from December 2019 to December 2020 were divided into control(61 cases) and treatment(60 cases) groups according to the grouping order. Patients in the control group were administered with Mometasone Furoate Aqueous Nasal Spray, 2 press/time, once daily. Patients in the treatment group were po administered with Danxiang Biyan Tablets, 4 tablets/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, the RQLQ scores, symptom scores, the serum IL-6, IL-27 and IFN-γlevels, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the control group was 81.97%, which was significantly lower than 95.00% of the treatment group(P < 0.05). After treatment,the RQLQ score and symptom score in two groups were significantly lower than those before treatment(P < 0.05), especially in the treatment group(P < 0.05). After treatment, the levels of serum IL-6 and IFN-γ in two groups were significantly decreased, while the level of IL-27 were significantly increased(P < 0.05), and the treatment group improved more significantly than the control group(P <0.05). During the treatment, the incidence of adverse reactions in the control group was significantly higher than that in the treatment group(19.67% vs 5.00%, P < 0.05). Conclusion Danxiang Biyan Tablets combined with mometasone furoate is effective in treatment of allergic rhinitis which can significantly improve the clinical symptoms and quality of life, and the incidence of adverse reactions is low.